Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia

NCT07363577 is registered in ClinicalTrials.gov with LB Pharmaceuticals Inc. as lead sponsor.

NCT NCT07363577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07363577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia
Lead sponsor
LB Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
March 25, 2026
Completion date
October 31, 2027
Enrollment
456 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia